Literature DB >> 19995939

Cardiovascular interactions between losartan and fructose in mice.

Danielle Senador1, Mary Key, K Bridget Brosnihan, Maria Claudia Irigoyen, Khalid M Elased, Mariana Morris.   

Abstract

AIM: To determine whether pharmacological blockade of angiotensin (Ang) AT1 receptors alters the cardiovascular, metabolic, and angiotensin-converting enzyme (ACE and ACE2) responses to a fructose diet in mice.
METHODS: C57BL male mice were fed with a 60% fructose diet for 8 weeks in combination with losartan treatment on week 9 (30 mg/kg per day). Blood pressure (BP), heart rate (HR), and autonomic balance were monitored using radiotelemetry with spectral analysis. Renal ACE and ACE2 activity and protein levels as well as Ang II and Ang 1-7 were measured.
RESULTS: Fructose impaired glucose tolerance and increased plasma cholesterol and insulin. These effects were not corrected by losartan treatment. Fructose increased BP and HR but only during the dark period. Short-term losartan treatment decreased BP by 16% in the fructose group but had no effect in controls. This was accompanied by a decrease in BP variance and its low-frequency component. Fructose increased Ang II (plasma and kidney) and ACE 2 (renal activity and protein expression). Losartan alone increased plasma Ang II in plasma and ACE2 in kidney. There were no changes in renal Ang 1-7 levels.
CONCLUSIONS: Losartan reversed the pressor effect of a high fructose diet, demonstrating that there are prominent interactions between a dietary regimen that produces glucose intolerance and an antihypertensive drug that antagonizes Ang signaling. The mechanism of change may be via renal Ang II rather than the ACE2/Ang 1-7 pathway because the fructose losartan combination resulted in lowered renal Ang II without changes in Ang 1-7.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19995939      PMCID: PMC3322615          DOI: 10.1177/1074248409351409

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol Ther        ISSN: 1074-2484            Impact factor:   2.457


  51 in total

Review 1.  Diabetic autonomic neuropathy. Cardiac sympathetic "dysinnervation," QT interval prolongation, and mortality.

Authors:  Dan Ziegler
Journal:  Clin Auton Res       Date:  2002-10       Impact factor: 4.435

2.  Characterization of renal angiotensin-converting enzyme 2 in diabetic nephropathy.

Authors:  Christos Tikellis; Colin I Johnston; Josephine M Forbes; Wendy C Burns; Louise M Burrell; John Risvanis; Mark E Cooper
Journal:  Hypertension       Date:  2003-02-24       Impact factor: 10.190

3.  Time- and frequency-domain estimation of early diabetic cardiovascular autonomic neuropathy.

Authors:  D Ziegler; D Laude; F Akila; J L Elghozi
Journal:  Clin Auton Res       Date:  2001-12       Impact factor: 4.435

4.  Hydrolysis of biological peptides by human angiotensin-converting enzyme-related carboxypeptidase.

Authors:  Chad Vickers; Paul Hales; Virendar Kaushik; Larry Dick; James Gavin; Jin Tang; Kevin Godbout; Thomas Parsons; Elizabeth Baronas; Frank Hsieh; Susan Acton; Michael Patane; Andrew Nichols; Peter Tummino
Journal:  J Biol Chem       Date:  2002-01-28       Impact factor: 5.157

5.  Increased ACE 2 and decreased ACE protein in renal tubules from diabetic mice: a renoprotective combination?

Authors:  Minghao Ye; Jan Wysocki; Parveen Naaz; Mohammad Reza Salabat; Michael S LaPointe; Daniel Batlle
Journal:  Hypertension       Date:  2004-04-12       Impact factor: 10.190

Review 6.  Insulin resistance and hypertension.

Authors:  James R Sowers
Journal:  Am J Physiol Heart Circ Physiol       Date:  2004-05       Impact factor: 4.733

7.  Cardiovascular and autonomic phenotype of db/db diabetic mice.

Authors:  Danielle Senador; Keerthy Kanakamedala; Maria Claudia Irigoyen; Mariana Morris; Khalid M Elased
Journal:  Exp Physiol       Date:  2009-02-13       Impact factor: 2.969

8.  Effect of imidapril, an angiotensin-converting enzyme inhibitor, on fructose-induced insulin resistance in rats.

Authors:  Tsuneyuki Oda; Masanobu Hirata; Yoshiharu Oshida; Yan-Qing Han; Keiichi Koshinaka; Yuzo Sato
Journal:  Endocr J       Date:  2004-02       Impact factor: 2.349

9.  Evidence for a causal role of the renin-angiotensin system in vascular dysfunction associated with insulin resistance.

Authors:  Kazuya Shinozaki; Kazuhide Ayajiki; Yoshihiko Nishio; Takeshi Sugaya; Atsunori Kashiwagi; Tomio Okamura
Journal:  Hypertension       Date:  2003-12-29       Impact factor: 10.190

10.  Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study.

Authors:  Lars H Lindholm; Hans Ibsen; Knut Borch-Johnsen; Michael Hecht Olsen; Kristian Wachtell; Björn Dahlöf; Richard B Devereux; Gareth Beevers; Ulf de Faire; Frej Fyhrquist; Stevo Julius; Sverre E Kjeldsen; Krister Kristianson; Ole Lederballe-Pedersen; Markku S Nieminen; Per Omvik; Suzanne Oparil; Hans Wedel; Peter Aurup; Jonathan M Edelman; Steven Snapinn
Journal:  J Hypertens       Date:  2002-09       Impact factor: 4.844

View more
  7 in total

1.  Advances in the renin angiotensin system focus on angiotensin-converting enzyme 2 and angiotensin-(1-7).

Authors:  Carlos M Ferrario; Sarfaraz Ahmad; Janae Joyner; Jasmina Varagic
Journal:  Adv Pharmacol       Date:  2010

2.  Sympathetic overactivity precedes metabolic dysfunction in a fructose model of glucose intolerance in mice.

Authors:  Katia De Angelis; Danielle D Senador; Cristiano Mostarda; Maria C Irigoyen; Mariana Morris
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2012-02-08       Impact factor: 3.619

Review 3.  Guidelines on models of diabetic heart disease.

Authors:  Lisa C Heather; Anne D Hafstad; Ganesh V Halade; Romain Harmancey; Kimberley M Mellor; Paras K Mishra; Erin E Mulvihill; Miranda Nabben; Michinari Nakamura; Oliver J Rider; Matthieu Ruiz; Adam R Wende; John R Ussher
Journal:  Am J Physiol Heart Circ Physiol       Date:  2022-06-03       Impact factor: 5.125

4.  Effects of restricted fructose access on body weight and blood pressure circadian rhythms.

Authors:  Danielle Senador; Swapnil Shewale; Maria Claudia Irigoyen; Khalid M Elased; Mariana Morris
Journal:  Exp Diabetes Res       Date:  2012-03-29

5.  Qingxuan Jiangya Decoction Mitigates Renal Interstitial Fibrosis in Spontaneously Hypertensive Rats by Regulating Transforming Growth Factor-β1/Smad Signaling Pathway.

Authors:  Wangyu Liu; Shan Lin; Qiaoyan Cai; Ling Zhang; Aling Shen; Youqin Chen; Jianfeng Chu; Jun Peng
Journal:  Evid Based Complement Alternat Med       Date:  2017-12-26       Impact factor: 2.629

6.  Overexpression of angiotensin-converting enzyme 2 by renin-angiotensin system inhibitors. Truth or myth? A systematic review of animal studies.

Authors:  Hisashi Kai; Mamiko Kai; Hiroshi Niiyama; Norihito Okina; Motoki Sasaki; Takanobu Maeda; Atsushi Katoh
Journal:  Hypertens Res       Date:  2021-03-10       Impact factor: 3.872

7.  Currently prescribed drugs in the UK that could upregulate or downregulate ACE2 in COVID-19 disease: a systematic review.

Authors:  Hajira Dambha-Miller; Ali Albasri; Sam Hodgson; Christopher R Wilcox; Shareen Khan; Nazrul Islam; Paul Little; Simon J Griffin
Journal:  BMJ Open       Date:  2020-09-14       Impact factor: 2.692

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.